Table 2.

Treatment characteristics and observed toxicities of the three trials that included pelvic lymph node irradiation.

Parameters	FASTR [28]	SATURN [38]	Murthy et al. 2018 [31]
Primary clinical target volume (CTV)	Prostate + 1 cm seminal vesicles (SV)	Prostate	Prostate + entire SV
Primary CTV to planning target volume (PTV)	5 mm	3 mm	5 mm (3 mm posteriorly)
Dose to prostate	40 Gy to PTV	40 Gy to CTV 33.25 Gy to PTV	35 Gy–37.5 Gy to PTV
Pelvic lymph node irradiation	25 Gy to PTV	25 Gy to CTV 23.75 Gy to PTV	25 Gy to PTV
Fractionation	Once weekly	Once weekly	Thrice weekly
Image guidance	Cone beam computed tomography (CBCT)	CBCT + fiducials	CBCT
Bladder dose constraints	V35 < 30% V29 < 50%	V35 < 5% V32 < 10%	V35 < 3% V17.5 < 20%
Rectum dose constraints	V35 < 20% V27 < 50%	V35 < 5% V32 < 10%	V35 < 3% V31.5 < 8% V28 < 15% V17.5 < 40%
Small bowel dose constraints	V25 < 190 cc V27.5 < 2 cc	V25 < 20 cc V30 < 2 cc	V28 < 80 cc
Median Follow-up	6 months	24 months	18 months
Grade 2+ acute gastrointestinal (GI) toxicity	0.0%	3.3%	4.0%
Grade 2+ acute genitourinary (GU) toxicity	25%	46.7%	12.0%
Grade 2+ late GI toxicity	50.1%	32.0%	4.0%
Grade 2+ late GU toxicity	37.5%	60.0%	7.0%